Lupin to acquire respiratory therapy brands from US-based Sunovion for $75-M

Publicly-listed, Mumbai-based Lupin Ltd (via its 100% subsidiary Lupin Inc, USA), is to acquire two inhalation-based respiratory therapy brands - Brovana and Xopenex HFA - from the US-based Sunovion Pharmaceuticals Inc, for USD 75 million in cash. The combined annual sales of the two brands being acquired is approximately USD 60 million.